Cmax is out of the range [Study As­sess­ment]

posted by Mikalai  – Belarus, 2018-08-01 12:05  – Posting: # 19121
Views: 2,328

Dear all,
We recently conducted a BE trial. It was a classical 2-period, 2-sequence study of a drug that consists of a combination of two active substances. Unfortunately, results one of analytes, a parent drug, fell sightly outside of the 80-125% range, below 80% for Cmax. CV was below 30% and post-hoc power was less than 80% for this analyte. Are there any ways we can defend bioequivalence without conducting another BE trail? All other analytes fell within 80-125%. Specifically, what should we put in the protocol or in a supporting letter to justify our lower border of CI around 79% for Cmax?

Complete thread:

Activity
 Admin contact
20,346 posts in 4,274 threads, 1,405 registered users;
online 6 (0 registered, 6 guests [including 2 identified bots]).
Forum time (Europe/Vienna): 05:51 CET

The belief that there is only one truth and
that oneself is in possession of it,
seems to me the deepest root of all
that is evil in the world.    Max Born

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5